DM

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
SLE, GMG, FDA, Systemic scleroderma, Research, CAR, CART, Report, American College, IND, Syndrome, Cyclophosphamide, MPV, MuSK protein, Dermatomyositis, Food, Nidec ASI, Myositis, Oxford, CD19, Molecular Therapy, Pemphigus, Good manufacturing practice, MG, Lupus, Conference, University, DM, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, American College of Rheumatology, Development, Wuxi, San Diego Convention Center, Disease, Scleroderma, Immunoglobulin therapy, GMP, Autoimmunity, Investment, Patient, ACR, Investigational New Drug, Pharmaceutical industry, Vaccine, Nightclub, Cryptocurrency, Cabaletta, Limited

PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • In November 2023, Cabaletta announced the Company’s fourth IND application for CABA-201 was cleared by the FDA for a Phase 1/2 study in patients with generalized myasthenia gravis (gMG).
  • Cabaletta will present new preclinical data for CABA-201 in a poster presentation and Cabaletta Bio Scientific Advisory Board members Carl June, M.D., and Georg Schett, M.D.
  • Cabaletta plans to participate in the following upcoming investor conferences:
    Stifel 2023 Healthcare Conference, which is being held from November 14-15, 2023 in New York, NY.
  • As of September 30, 2023, Cabaletta had cash, cash equivalents and short-term investments of $164.4 million, compared to $106.5 million as of December 31, 2022.

Desktop Metal Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Hardware, Manufacturing, Technology, Machine Tools, Metalworking & Metallurgy, Software, Carbon, Metal, ETEC, Carbon (company), Event, NYSE, Desktop Metal, EBITDA, DLP, DM, GAAP, Phase 10, Deathmatch, Stratasys, Investment, 3D printing, Video game, Bank, Bookkeeping

Desktop Metal, Inc. (NYSE: DM), a global leader in Additive Manufacturing 2.0 technologies for mass production, today announced its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Desktop Metal, Inc. (NYSE: DM), a global leader in Additive Manufacturing 2.0 technologies for mass production, today announced its financial results for the third quarter ended September 30, 2023.
  • “Revenue in the third quarter was disappointing for Desktop Metal and also for the entire additive manufacturing industry.
  • See “Non-GAAP Financial Information.”
    Desktop Metal will host a conference call on Thursday, November 9, 2023 to discuss third quarter 2023 results.
  • Participants may access the call at 1-877-407-4018, international callers may use 1-201-689-8471, and request to join the Desktop Metal financial results conference call.

Desktop Metal Announces Updated Third Quarter 2023 Earnings Call Time

Retrieved on: 
Tuesday, November 7, 2023
Hardware, Manufacturing, Technology, Machine Tools, Metalworking & Metallurgy, Software, Metal, DM, Event, NYSE, Webcast, Desktop Metal, Cryptocurrency, Online shopping, Consumer electronics

Desktop Metal, Inc. (NYSE: DM) today announced that it will be holding its previously announced conference call five hours earlier to better coincide with timing of the Company’s earnings release.

Key Points: 
  • Desktop Metal, Inc. (NYSE: DM) today announced that it will be holding its previously announced conference call five hours earlier to better coincide with timing of the Company’s earnings release.
  • Company management will now host the conference call and webcast on third quarter 2023 financial results on November 9, 2023 at 7:00 a.m.
  • Participants may access the call at 1-877-407-4018, international callers may use 1-201-689-8471, and request to join the Desktop Metal financial results conference call.
  • A simultaneous webcast of the conference call and the accompanying summary presentation may be accessed online at the Events & Presentations section of https://ir.desktopmetal.com .

Expensify Announces Q3 2023 Results

Retrieved on: 
Tuesday, November 7, 2023
Professional Services, Payments, Apps, Applications, Technology, Software, Finance, Accounting, Sale, IPO, ARPU, FY, RSU, SEM, Interchange, EBITDA, VSB, DM, Accountability partner, Engineering, Contra, Environment, WhatsApp, SEO, SMB, Channel, Instability, Mining, Online shopping, Bookkeeping, Bank, Security (finance), Life insurance, Expensify

With luck, our long-awaited migration of Expensify Classic to New Expensify should be actively underway by this time next quarter.

Key Points: 
  • With luck, our long-awaited migration of Expensify Classic to New Expensify should be actively underway by this time next quarter.
  • Expensify Card accounting treatment - The company will become the program manager of the Expensify Card starting in late Q4.
  • The following statements are forward-looking and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below.
  • There can be no assurance that the Company will achieve the results expressed by this guidance.

Bexacat™ (bexagliflozin tablets), the First and Only Tablet to Treat Feline Diabetes, Named “Overall Cat Health Product Of The Year” In 2023 Pet Innovation Awards

Retrieved on: 
Thursday, November 2, 2023
Science, FDA, Research, Retail, Veterinarian, NYSE, Innovation, Food, Diabetes, Vomiting, Human, Cat, Weight loss, Diarrhea, Elanco, Service, DM, SGLT2, Argyreia nervosa, Liver, Type 1 diabetes, Pancreatitis, ELAN, Urine, Dehydration, Disease, Risk, Farmer, Lethargy, Depression, Diabetic ketoacidosis, Pet, Diagnosis, Death, Glucose, Coma, Insulin, Pharmaceutical industry, Health, Housing

Bexacat is a once-daily tablet that works to lower blood sugar by increasing urine excretion of glucose through inhibition of sodium-glucose cotransporter 2 (SGLT2).

Key Points: 
  • Bexacat is a once-daily tablet that works to lower blood sugar by increasing urine excretion of glucose through inhibition of sodium-glucose cotransporter 2 (SGLT2).
  • “Bexacat removes some of the traditional challenges associated with treating feline diabetes and is a more efficient option for today’s on-the-go pet owner lifestyle.
  • Bexacat is needle-free and dosed to felines at a minimum weight of 6.6 lbs in order to ensure dosing accuracy.
  • The 2023 Pet Innovation Awards attracted more than 2,000 nominations from around the world.

Desktop Metal to Release Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Retrieved on: 
Friday, November 3, 2023
Machine Tools, Metalworking & Metallurgy, Technology, Manufacturing, Other Technology, Software, Other Manufacturing, Hardware, Metal, DM, Event, NYSE, Desktop Metal, 3D printing, Consumer electronics, Online shopping

Desktop Metal, Inc. (NYSE: DM) today announced it will report financial results for the third quarter ended September 30, 2023 before the market opens on Thursday, November 9, 2023.

Key Points: 
  • Desktop Metal, Inc. (NYSE: DM) today announced it will report financial results for the third quarter ended September 30, 2023 before the market opens on Thursday, November 9, 2023.
  • At this time, a summary presentation will also be available online at the Events & Presentations section of Desktop Metal’s Investor Relations website, https://ir.desktopmetal.com .
  • Desktop Metal will host a conference call on the same day at 12:00 p.m.
  • Participants may access the call at 1-877-407-4018, international callers may use 1-201-689-8471, and request to join the Desktop Metal financial results conference call.

Desktop Health™ Announces Hannover Medical School Has Implanted the First Adult Custom Ear Implant with Drug Release Benefits Manufactured on the 3D-Bioplotter®

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Surgery, Medical Devices, Health, Health Technology, Desktop, Anatomy, 3D, ENT, FDA, Desktop Metal, Kool-Aid, PD, NYSE, MHH, Person, Hannover Medical School, DM, Research, Multimedia, Medicine, Sensorineural hearing loss, Tinnitus, DHZ, Patient, Diagnosis, Otorhinolaryngology, 3D bioprinting, 3D printing, Dentistry, Medical device, MD

View the full release here: https://www.businesswire.com/news/home/20231031818640/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231031818640/en/
    The ENT clinic at Hannover Medical School (MHH) in Germany has used its Desktop Health 3D-Bioplotter to produce a customized ear implant with drug release benefits for implantation in an adult patient.
  • A growing number of parts bioprinted on the 3D-Bioplotter are being used in patients.
  • “Our entire team celebrates this important accomplishment by the Hannover Medical School ENT clinic, which has been years in the making,” said Ric Fulop, Founder and CEO of Desktop Metal.
  • The MHH ENT Clinic is internationally renowned for the world's largest cochlear implant program for the care of hearing-impaired patients.

Desktop Metal and Schaeffler to Collaborate on Additive Manufacturing of Multi-Material Powders, including Metals and Ceramics

Retrieved on: 
Thursday, October 26, 2023
Machine Tools, Metalworking & Metallurgy, Electronic Design Automation, Technology, Photography, Manufacturing, Hardware, Metal, SPD, Schaeffler Group, NYSE, Desktop Metal, DM, Senior, Ceramic, 3D printing

Desktop Metal, Inc. (NYSE: DM), a global leader in Additive Manufacturing 2.0 technologies for mass production of metal, ceramic, polymer, and health products, today announced that it is collaborating with Schaeffler AG, the German motion technology company, on additive manufacturing of multi-material powders, including metal and ceramics.

Key Points: 
  • Desktop Metal, Inc. (NYSE: DM), a global leader in Additive Manufacturing 2.0 technologies for mass production of metal, ceramic, polymer, and health products, today announced that it is collaborating with Schaeffler AG, the German motion technology company, on additive manufacturing of multi-material powders, including metal and ceramics.
  • “Schaeffler is one of the leading global manufacturers of components and systems as well as bearing solutions.
  • The motion technology company has a longstanding excellence in precision mechanical engineering and an innovative mindset open to integrate new production processes like metal multi-material printing.
  • We’re excited to collaborate with the experienced team on next-generation multi-material additive manufacturing,” said Ric Fulop, Founder and CEO of Desktop Metal.

University of Phoenix College of Doctoral Studies Announces Winners of Inaugural President’s Award for Excellence in Diversity, Equity, Inclusion and Belonging in Research, Scholarship and Dissertation

Retrieved on: 
Thursday, October 26, 2023
Professional Services, Continuing, University, DEI (Diversity, Equity and Inclusion), Education, Knowledge, Online, Woman, University of Phoenix, African Americans, Value, Thesis, McDowell, DBA, Inclusion, DM, Law enforcement, Doctor, Center for Digital Research and Scholarship, Admission, DEIB, Evaluation, Phoenix College, Generation, KWB, Nursing, Auction, Research, Belonging

The University of Phoenix College of Doctoral Studies announced the winners of the inaugural President’s Award for Excellence in Diversity, Equity, Inclusion and Belonging in Research, Scholarship and Dissertation at its annual Knowledge Without Boundaries (KWB) Research Summit on October 13, 2023.

Key Points: 
  • The University of Phoenix College of Doctoral Studies announced the winners of the inaugural President’s Award for Excellence in Diversity, Equity, Inclusion and Belonging in Research, Scholarship and Dissertation at its annual Knowledge Without Boundaries (KWB) Research Summit on October 13, 2023.
  • All winners and nominees were recognized a presentation of the awards by University of Phoenix President Chris Lynne.
  • “Supporting diversity and building inclusivity have always been guiding tenets of University of Phoenix,” states Lynne.
  • Eligibility for the Research and Scholarship awards was open across the University, and the category of Dissertation was open to doctoral students who successfully defended their dissertation within the past year.

ROMPE PECHITO ®, New Product With Natural Extracts for Children’s Cough Relief

Retrieved on: 
Wednesday, October 25, 2023
Health, Consumer, Other Health, Children, General Health, Pharmaceutical, Hispanic, Honey, FDA, Temperature, Dextromethorphan, Food, Cough, Common, Laboratory, DM, Mucus, Multimedia, Immune system, Rompe, Pharmacy, Guaifenesin, Food and Drug Administration, Pharmaceutical industry, Dietary supplement

Recently Efficient Laboratories, a Puerto Rican company dedicated to the distribution of its own health care brands, launched a new product, ROMPE PECHITO ®, an over-the-counter medicine for children to relieve cold symptoms.

Key Points: 
  • Recently Efficient Laboratories, a Puerto Rican company dedicated to the distribution of its own health care brands, launched a new product, ROMPE PECHITO ®, an over-the-counter medicine for children to relieve cold symptoms.
  • View the full release here: https://www.businesswire.com/news/home/20231025483780/en/
    Rompe Pechitos® DM is the newest addition to our Rompe Pecho® family.
  • This product is based on a natural ingredient formula with honey and elderberry extract that has proven effective in treating symptoms associated with colds.
  • It is recommended to consult a doctor or pharmacist if you have any questions, and use the product as directed.